Drugs / CL184
CL184
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01228383 | Dec 2011 → Oct 2012 | rabies | Crucell Holland BV | Completed | No outcome recorded |
| Phase 2 | NCT00708084 | May → Oct 2008 | rabies | Crucell Holland BV | Completed | No outcome recorded |
| Phase 2 | NCT00656097 | Mar → Jul 2008 | rabies | Crucell Holland BV | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CL184 | “CL184 20 IU/kg intramuscularly on Day 0.” NCT01228383 ↗ |
| Known as | CR-57/CR-4098 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109564 ↗ |
| Known as | MIX OF CR-57 AND CR-4098 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109564 ↗ |
| Modality | Monoclonal antibody | “The aim of this study is to evaluate the safety of the monoclonal antibody cocktail CL184 in combination with rabies vaccine compared with human rabies immune globulin (HRIG)...” NCT00656097 ↗ |
| Route | Intramuscular | “CL184 20 IU/kg intramuscularly on Day 0” NCT00656097 ↗ |